Pipeline

Tes Pharma is focused on delivering proprietary first-in-class drug candidates for oncology, metabolic and renal diseases.

Target
(Disease) Disease
Discovery
Preclinical
Clinical

INT-787

FXR Agonist (TC-100)

Licensed to Intercept Pharmaceuticals

Severe Alcohol-associated Hepatitis

TES-AKI-01

ACMSD Inhibitor

Acute Kidney Injury

TES-ONC-07

NR2F6 Antagonist

Cancer Immunotherapy

TES-ONC-0x

Undisclosed Target

Cancer